MRVI Q4 2022 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$205M-10.4% YoY

Gross Profit

$151M74.0% margin

Operating Income

$109M53.4% margin

Net Income

$38M18.4% margin

EPS (Diluted)

$0.66

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

$99M

Free Cash Flow

$93M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.4B

Stockholders' Equity

$545M

Cash & Equivalents

$632M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$205M	$228M	-10.4%
Gross Profit	$151M	$188M	-19.4%
Operating Income	$109M	$151M	-27.7%
Net Income	$38M	$55M	-32.1%

Revenue Segments

Nucleic Acid Production Segment

$189M92%

Biologics Safety Testing Segment

$15M8%